Benefits
Reported Mood Lift (Anecdotal, Not Tested)
No controlled trial has ever tested PEA on its own for mood or focus, so reports of a brief lift after taking it are anecdotal rather than measured. The enzyme MAO-B breaks oral PEA down within minutes, which leaves very little room for any lasting effect, and individual response varies widely. Effects should not be expected to last like caffeine or other stimulants.
Trace Amine Pathway (Laboratory Research Only)
PEA is an endogenous neuromodulator that activates trace amine-associated receptors (TAAR1), which influence dopamine and norepinephrine signaling. Whether swallowing PEA meaningfully changes this system in people has never been tested; the TAAR1 work is laboratory and animal research, and oral PEA is largely destroyed by MAO-B before it can act.
Common Pre-Workout Blend Ingredient
PEA is often included as one ingredient in multi-ingredient pre-workout blends. No study has separated out what PEA itself contributes in those products, so any focus or energy people notice cannot be credited to PEA rather than to the caffeine and other stimulants alongside it.
Endogenous Chocolate Compound
PEA occurs naturally in chocolate and aged cheeses at low levels and is part of the family of trace amines normally present in the human brain. Being naturally present in food and in the body does not by itself show that a supplement dose does anything useful, and no study has tested whether raising PEA intake changes how a person feels or performs.
Mechanism of action
Catecholamine Release Promotion
In laboratory and animal research, PEA triggers release of dopamine and norepinephrine in the brain, which is where its stimulant-like reputation comes from. This has not been shown to produce a measured mood, energy or focus effect in people taking PEA by mouth, because MAO-B breaks it down within minutes.
TAAR1 Receptor Agonism
PEA is an agonist at trace amine-associated receptor 1 (TAAR1), a G-protein-coupled receptor that modulates dopaminergic and serotonergic activity. TAAR1 signaling is studied in mood, motivation and addiction-related brain circuits, but this is preclinical research, and no human trial has linked a PEA supplement to changes in those pathways.
Rapid MAO-B Degradation
Oral PEA is degraded within minutes by monoamine oxidase B in gut wall, liver, and brain, producing phenylacetic acid. This rapid metabolism explains why subjective effects from standalone PEA supplements are very brief and why MAO-B inhibition dramatically prolongs activity (and risk).
Clinical trials
A 1996 report in J Neuropsychiatry Clin Neurosci, indexed by PubMed under Case Reports, describing people already diagnosed with depression who took phenylethylamine (10 to 60 mg per day) together with low-dose selegiline, a prescription MAO-B inhibitor drug. (Sabelli et al, PMID 9081552)
Adults being treated for major depressive disorder. Case report format: no control group, no randomization, no blinding, and no placebo comparison.
The authors reported lasting improvement in mood in patients given PEA together with selegiline. Because this is a case report with no comparison group and no blinding, it cannot show that PEA caused the improvement and it is wide open to selective reporting. The improvement also depended on a prescription MAO-B inhibitor drug to stop PEA being destroyed within minutes, so it says nothing about a PEA supplement taken alone, and nothing about how PEA affects a healthy person. This is not evidence that PEA treats or prevents depression. The PEA plus selegiline combination carries a risk of hypertensive crisis and must not be attempted outside specialist medical care.
Background reading on how PEA behaves in the body: it is made in the body from the amino acid L-phenylalanine, acts at TAAR1 receptors, releases monoamines in laboratory models, and is broken down very quickly by MAO-B. This is review material rather than a study in people, and no PMID is listed for it on this page.
Narrative review of preclinical pharmacology and clinical literature.
The takeaway is that PEA is a naturally occurring trace amine that acts on brain monoamines in laboratory models but survives only briefly in the body when swallowed. Any sustained brain effect would require blocking MAO-B, which is exactly the combination that risks a hypertensive crisis. Its pharmacology is not identical to amphetamine but overlaps with monoamine-releasing stimulants. A review summarizes other people's research and cannot on its own demonstrate a benefit.